Avisi Technologies Appoints Healthcare Industry Leader, Gary J. Pruden, to Board of Directors

Share Article

Avisi Technologies, Inc., an ophthalmic medical device company dedicated to improving patient outcomes in the glaucoma field, announced today the appointment of Gary J. Pruden to its Board of Directors. Pruden, who previously served as Executive Vice President and Worldwide Chairman for the Johnson & Johnson ("J&J") Medical Devices group, brings decades of commercial and C-suite experience in growing and developing organizations, and driving innovation in the healthcare sector.

Avisi Technologies, Inc., an ophthalmic medical device company dedicated to improving patient outcomes in the glaucoma field, announced today the appointment of Gary J. Pruden to its Board of Directors. Pruden, who previously served as Executive Vice President and Worldwide Chairman for the Johnson & Johnson ("J&J") Medical Devices group, brings decades of commercial and C-suite experience in growing and developing organizations, and driving innovation in the healthcare sector.

"We are thrilled to welcome Gary to our Board of Directors,” said Rui Jing Jiang, CEO of Avisi. “VisiPlate® will be the first multi-channel, non-fibrotic, nanotechnology-enabled implant solution seeking to meet the market needs of sustained efficacy and improved quality of life for glaucoma patients around the world. I look forward to working closely with Gary in accelerating its development and commercialization.”

“I am excited about the potential of the VisiPlate® technology. Having family members with glaucoma, I have seen firsthand the current limitations of therapeutic interventions,” said Gary Pruden.

About Glaucoma and its Treatment:
Glaucoma is the second leading cause of blindness, affecting over 90 million people worldwide. The market for surgical solutions is growing close to 20 percent per year as global populations age and diagnostic technologies improve. Current treatments remain limited in terms of either patient compliance, sustained efficacy, invasiveness, or needing revision, and the need for better technologies persists.

About Avisi Technologies, Inc.:
Avisi Technologies, Inc., is a preclinical stage startup company developing a multi-channel, nanotechnology-enabled implant called VisiPlate®. Avisi has been funded by the National Science Foundation, the University of Pennsylvania, and private investment. Avisi is also a Johnson & Johnson JLABS incubated company, a MedTech Innovator Accelerator company, and a UCSF Rosenman Innovator. Key scientific advisors include Eydie Miller-Ellis, MD (Scheie Eye Institute), Richard A. Lewis, MD (Sacramento Eye Consultants), Ike K. Ahmed, MD, FRCSC (Prism Eye Institute), Vivian Lee, MD (Scheie Eye Institute), Samuel Nicaise, PhD, and Thomas A. Barbolt, PhD. Avisi has been recognized as one of the ten most promising Philadelphia tech companies of the decade by Technical.ly, a Watchlist venture by Wharton Magazine, and was a finalist at the 2019 SXSW Innovation Awards.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rui Jing Jiang
@avisi_tech
since: 06/2019
Follow >
Visit website